Clinical trial · Interventional
Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer
Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer: Study Phase II Clinical Trial
NCT02080962CI-TRIAL-00013980terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low rate of recruitment.
Summary
Brief summary (as posted)
Radiotherapy is a treatment considered standard for non melanoma skin cancer. This institution uses schemes of 4 to 6 weeks of treatment. The objective of the study is to perform radiation therapy in 1 to 2 weeks, depending on the size of the lesion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-melanoma Skin Cancer | Skin Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 30 Gy in 5 fractions | Radiation | — | UNRESOLVED |
| 40 Gy in 10 fractions | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 30 Gy in 5 fractions of 6 Gy
- description
- tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89
- interventionNames
- Radiation: 30 Gy in 5 fractions
- type
- EXPERIMENTAL
- label
- 40 Gy in 10 fractions of 4 Gy
- description
- tumors \> 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
- interventionNames
- Radiation: 40 Gy in 10 fractions
Primary outcomes (1)
- measure
- Rate of complete remission with hypofractionated RT schemes for NMSC.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cosmesis not important * Basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of any differentiation * Clinical stage I and II * Location on the thorax, abdomen, pelvis (except perineum), arm, thigh, cheek * Patient with up to 3 injuries eligible for the study * Karnofsky Performance Status (KPS) ≥ 70% * Age \> 18 years * Informed Consent signed by the patient consenting to undergo the study Exclusion Criteria: * Indian Race * Prior treatment for their skin cancer * More than three synchronous lesions to treatment with RT * Basal syndrome, xeroderma, vitiligo and albinism * Immunosuppression * Prior burn at the tumor site * Tumor \> 5 cm * Age \<18 years * Carrier mental incapacity * People in a relationship of dependence as prisoners, soldiers, students, staff, etc..
References
Publications (0)
Data not yet available
No reference posted for this study.